Home ›
Lung Cancer Trials ›
NCT04996121
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
Trial Details
NCT ID NCT04996121 Phase PHASE1 / PHASE2
Sponsor Xuanzhu Biopharmaceutical Co., Ltd.
Status RECRUITING
Cancer Type Lung Cancer
Interventions Locations (sample) Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
Male or female subjects aged ≥18 years old; Phase I dose escalation period: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor, assessed by inv… Phase I dose expansion cohort 1 and Phase II cohort 1: locally advanced, or metastatic solid tumor with NTRK gene fusion Phase I dose expansion coh… phase I dose escalation: at least 1 measurable target lesion according to RECIST version 1.1 Phase I dose expansion and Phase II: at least 1 measur… For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →